An observational study in Mental Disorders and Healthy Control, sponsored by mingjun Zhong. Recruiting at 1 site in China. Open to participants aged 13 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-13.
Sponsored by mingjun Zhong · Observational
This study focuses on the structure and function of the brain and gene expression in peripheral blood of patients with schizophrenia, to explore the interaction and influence between the three. Patients with mental disorders who have been recruited will take their medication regularly for 1 year and participate in baseline and follow-up assessments.
The study seeks to identify possible biological markers of schizophrenia and the effects of gene-environment interactions on brain structural and functional networks. So we can help doctors and scientific researchers better understand the neuropathological basis of schizophrenia.
2,107 studies on the registry are indexed under Mental Disorders; 416 are open to participants now.
This study's planned enrollment of 1,899 is above the median of 200 across 480 observational studies indexed under Mental Disorders.
Browse Mental Disorders studies →This is the only study on the registry with mingjun Zhong as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Patients from inpatient and outpatient the second Xiangya Hosptial of Central South University, Healthy controls from community, school and street recruitment
Exclusion Criteria:
Healthy Norms
Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids
Subclinical high-risk
Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids
Schizophrenia and Psychosis patient
Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids
major depressive disorder patient
Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids
autism spectrum disorder patient
Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids
bipolar disorder patient
Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids
Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.
cortical morphology
Data were obtained using magnetic resonance scans
Time frame: 40 minutes
target gene charaacteristics
10ml peripheral blood was extracted for gene analysis
Time frame: 1 day
scale scores
The score of each dimension and the total score were calculated according to the scale.The scale includes three dimensions: negative symptom, positive symptom and general psychopathology, and the score range of each dimension is different. The total score ranges from 30 to 210, with higher scores indicating worse results.
Time frame: 90 minutes.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.